New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2013
10:10 EDTROSGRosetta Genomics surges after announcing study publication
Shares of Rosetta Genomics (ROSG), which develops and commercializes microRNA-based molecular diagnostics, advanced in early trading after the company announced the recent publication of data from a study assessing the differences between cancer of unknown primary, or CUP, and metastatic solid tumors of known primary metastases, or KPM, by profiling microRNA expression. According to the company's press release, the study's author, George Pentheroudakis, said, "This research is the first look for microRNA characteristics of CUP tumors. Study results confirmed epidemiologic evidence suggesting that patients with favorable prognosis CUP have a presentation, response to therapy and outcome no different from metastatic tumors of matched primaries." The company's CEO said, "This publication demonstrates the utility of microRNA profiling in understanding the biology of CUP and may have important implications for the prognosis and treatment of CUP patients," adding that the company looks forward to the publication of the full data set. The company offered a link to an abstract of the study, which had an e-publication date of Nov. 4, 2012 ahead of its print publication, according to the post on the site of the U.S. National Library of Medicine and National Institutes of Health. In early morning trading, Rosetta Genomics shares rose $1.02, or 22.05% to $5.62. Reference Link
News For ROSG From The Last 14 Days
Check below for free stories on ROSG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
12:28 EDTROSGRosetta Genomics to host business news update conference call
Business News Update Conference call to be held on September 18 at 10 am. Webcast Link
September 3, 2014
08:18 EDTROSGRosetta Genomics initiates post-marketing registry study of Cancer Origin Test
Subscribe for More Information
September 2, 2014
08:21 EDTROSGRosetta Genomics, Moffitt Cancer enter cancer diagnostics alliance
Rosetta Genomics announces that the company has entered into a strategic alliance with Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, to discover, develop and commercialize a variety of microRNA-based cancer diagnostics. Under the three-year alliance Rosetta will provide funding for Moffitt investigator-initiated projects that align with Rosetta's strategic priorities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use